Array ( [0] => Array ( [ID] => 1369 [~ID] => 1369 [IBLOCK_ID] => 35 [~IBLOCK_ID] => 35 [IBLOCK_SECTION_ID] => [~IBLOCK_SECTION_ID] => [NAME] => Expert board: "Possibilities of etiotropic therapy for respiratory infections caused by RNA viruses" [~NAME] => Expert board: "Possibilities of etiotropic therapy for respiratory infections caused by RNA viruses" [ACTIVE_FROM] => 26.04.2021 17:13:00 [~ACTIVE_FROM] => 26.04.2021 17:13:00 [TIMESTAMP_X] => 26.01.2022 17:47:29 [~TIMESTAMP_X] => 26.01.2022 17:47:29 [DETAIL_PAGE_URL] => /en/research/ekspertnyy-sovet-vozmozhnosti-etiotropnoy-terapii-respiratornykh-infektsiy-vyzvannykh-rnk-virusami/ [~DETAIL_PAGE_URL] => /en/research/ekspertnyy-sovet-vozmozhnosti-etiotropnoy-terapii-respiratornykh-infektsiy-vyzvannykh-rnk-virusami/ [LIST_PAGE_URL] => /en/research/ [~LIST_PAGE_URL] => /en/research/ [DETAIL_TEXT] => On April 26, 2021, in Moscow, under the auspices of the consortium of the academic community for the study of coronavirus infection, an expert council of the Russian Scientific Medical Society of Physicians was held dedicated to modern aspects of etiotropic therapy for the new coronavirus infection and other diseases caused by RNA viruses.



[~DETAIL_TEXT] => On April 26, 2021, in Moscow, under the auspices of the consortium of the academic community for the study of coronavirus infection, an expert council of the Russian Scientific Medical Society of Physicians was held dedicated to modern aspects of etiotropic therapy for the new coronavirus infection and other diseases caused by RNA viruses.



[DETAIL_TEXT_TYPE] => html [~DETAIL_TEXT_TYPE] => html [PREVIEW_TEXT] => On April 26, 2021, in Moscow, under the auspices of the consortium of the academic community for the study of coronavirus infection, an expert council of the Russian Scientific Medical Society of Physicians was held dedicated to modern aspects of etiotropic therapy for the new coronavirus infection and other diseases caused by RNA viruses. [~PREVIEW_TEXT] => On April 26, 2021, in Moscow, under the auspices of the consortium of the academic community for the study of coronavirus infection, an expert council of the Russian Scientific Medical Society of Physicians was held dedicated to modern aspects of etiotropic therapy for the new coronavirus infection and other diseases caused by RNA viruses. [PREVIEW_TEXT_TYPE] => text [~PREVIEW_TEXT_TYPE] => text [PREVIEW_PICTURE] => Array ( [ID] => 1615 [TIMESTAMP_X] => Bitrix\Main\Type\DateTime Object ( [userTimeEnabled:protected] => 1 [value:protected] => DateTime Object ( [date] => 2022-01-26 17:47:29.000000 [timezone_type] => 3 [timezone] => Europe/Moscow ) ) [MODULE_ID] => iblock [HEIGHT] => 882 [WIDTH] => 1500 [FILE_SIZE] => 304153 [CONTENT_TYPE] => image/jpeg [SUBDIR] => iblock/40c/1tkswd7eiuvdvvf6fxqlivk3ixyqgjdc [FILE_NAME] => r_pm_6.jpg [ORIGINAL_NAME] => r_pm_6.jpg [DESCRIPTION] => [HANDLER_ID] => [EXTERNAL_ID] => ada2fd024afd8b48918093f6ddfa47a1 [~src] => [SRC] => /upload/iblock/40c/1tkswd7eiuvdvvf6fxqlivk3ixyqgjdc/r_pm_6.jpg [UNSAFE_SRC] => /upload/iblock/40c/1tkswd7eiuvdvvf6fxqlivk3ixyqgjdc/r_pm_6.jpg [SAFE_SRC] => /upload/iblock/40c/1tkswd7eiuvdvvf6fxqlivk3ixyqgjdc/r_pm_6.jpg [ALT] => Expert board: "Possibilities of etiotropic therapy for respiratory infections caused by RNA viruses" [TITLE] => Expert board: "Possibilities of etiotropic therapy for respiratory infections caused by RNA viruses" ) [~PREVIEW_PICTURE] => 1615 [LANG_DIR] => /en/ [~LANG_DIR] => /en/ [CODE] => ekspertnyy-sovet-vozmozhnosti-etiotropnoy-terapii-respiratornykh-infektsiy-vyzvannykh-rnk-virusami [~CODE] => ekspertnyy-sovet-vozmozhnosti-etiotropnoy-terapii-respiratornykh-infektsiy-vyzvannykh-rnk-virusami [EXTERNAL_ID] => 1369 [~EXTERNAL_ID] => 1369 [IBLOCK_TYPE_ID] => informationLang [~IBLOCK_TYPE_ID] => informationLang [IBLOCK_CODE] => [~IBLOCK_CODE] => [IBLOCK_EXTERNAL_ID] => 33 [~IBLOCK_EXTERNAL_ID] => 33 [LID] => en [~LID] => en [EDIT_LINK] => [DELETE_LINK] => [DISPLAY_ACTIVE_FROM] => 26 April 2021 [FIELDS] => Array ( ) [PROPERTIES] => Array ( [SOURCE] => Array ( [ID] => 185 [IBLOCK_ID] => 35 [NAME] => Направление [ACTIVE] => Y [SORT] => 100 [CODE] => SOURCE [DEFAULT_VALUE] => [PROPERTY_TYPE] => L [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => Y [XML_ID] => 177 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Направление [~DEFAULT_VALUE] => [VALUE_ENUM] => Array ( [0] => Treatment for COVID-19 ) [VALUE_XML_ID] => Array ( [0] => covid ) [VALUE_SORT] => Array ( [0] => 100 ) [VALUE] => Array ( [0] => Treatment for COVID-19 ) [PROPERTY_VALUE_ID] => Array ( [0] => 115320 ) [VALUE_ENUM_ID] => Array ( [0] => 168 ) [DESCRIPTION] => Array ( [0] => ) [~VALUE] => Array ( [0] => Treatment for COVID-19 ) [~DESCRIPTION] => Array ( [0] => ) ) [LINK] => Array ( [ID] => 186 [IBLOCK_ID] => 35 [NAME] => Ссылка [ACTIVE] => Y [SORT] => 200 [CODE] => LINK [DEFAULT_VALUE] => [PROPERTY_TYPE] => S [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => N [XML_ID] => 188 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Ссылка [~DEFAULT_VALUE] => [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [VALUE] => [PROPERTY_VALUE_ID] => [DESCRIPTION] => [~DESCRIPTION] => [~VALUE] => ) [FILES] => Array ( [ID] => 187 [IBLOCK_ID] => 35 [NAME] => Файлы [ACTIVE] => Y [SORT] => 900 [CODE] => FILES [DEFAULT_VALUE] => [PROPERTY_TYPE] => F [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => Y [XML_ID] => 182 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => Y [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Файлы [~DEFAULT_VALUE] => [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [VALUE] => Array ( [0] => 1611 [1] => 1612 ) [PROPERTY_VALUE_ID] => Array ( [0] => 115308 [1] => 115309 ) [DESCRIPTION] => Array ( [0] => Resolution of the Council of Experts [1] => Members of the Expert Council ) [~VALUE] => Array ( [0] => 1611 [1] => 1612 ) [~DESCRIPTION] => Array ( [0] => Resolution of the Council of Experts [1] => Members of the Expert Council ) ) ) [DISPLAY_PROPERTIES] => Array ( [SOURCE] => Array ( [ID] => 185 [IBLOCK_ID] => 35 [NAME] => Направление [ACTIVE] => Y [SORT] => 100 [CODE] => SOURCE [DEFAULT_VALUE] => [PROPERTY_TYPE] => L [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => Y [XML_ID] => 177 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Направление [~DEFAULT_VALUE] => [VALUE_ENUM] => Array ( [0] => Treatment for COVID-19 ) [VALUE_XML_ID] => Array ( [0] => covid ) [VALUE_SORT] => Array ( [0] => 100 ) [VALUE] => Array ( [0] => Treatment for COVID-19 ) [PROPERTY_VALUE_ID] => Array ( [0] => 115320 ) [VALUE_ENUM_ID] => Array ( [0] => 168 ) [DESCRIPTION] => Array ( [0] => ) [~VALUE] => Array ( [0] => Treatment for COVID-19 ) [~DESCRIPTION] => Array ( [0] => ) [DISPLAY_VALUE] => Treatment for COVID-19 ) ) [IPROPERTY_VALUES] => Array ( ) ) [1] => Array ( [ID] => 1370 [~ID] => 1370 [IBLOCK_ID] => 35 [~IBLOCK_ID] => 35 [IBLOCK_SECTION_ID] => [~IBLOCK_SECTION_ID] => [NAME] => Summary report on results of clinical trial of medicinal product Areplivir [~NAME] => Summary report on results of clinical trial of medicinal product Areplivir [ACTIVE_FROM] => 17.08.2020 17:15:00 [~ACTIVE_FROM] => 17.08.2020 17:15:00 [TIMESTAMP_X] => 26.01.2022 17:50:06 [~TIMESTAMP_X] => 26.01.2022 17:50:06 [DETAIL_PAGE_URL] => /en/research/summary-report/ [~DETAIL_PAGE_URL] => /en/research/summary-report/ [LIST_PAGE_URL] => /en/research/ [~LIST_PAGE_URL] => /en/research/ [DETAIL_TEXT] => [~DETAIL_TEXT] => [DETAIL_TEXT_TYPE] => text [~DETAIL_TEXT_TYPE] => text [PREVIEW_TEXT] => Open randomized multicenter comparative study on the efficacy and safety of AREPLIVIR film-coated tablets (PROMOMED RUS LLC, Russia) in patients hospitalized with COVID-19 [~PREVIEW_TEXT] => Open randomized multicenter comparative study on the efficacy and safety of AREPLIVIR film-coated tablets (PROMOMED RUS LLC, Russia) in patients hospitalized with COVID-19 [PREVIEW_TEXT_TYPE] => text [~PREVIEW_TEXT_TYPE] => text [PREVIEW_PICTURE] => Array ( [ID] => 1614 [TIMESTAMP_X] => Bitrix\Main\Type\DateTime Object ( [userTimeEnabled:protected] => 1 [value:protected] => DateTime Object ( [date] => 2022-01-26 17:50:06.000000 [timezone_type] => 3 [timezone] => Europe/Moscow ) ) [MODULE_ID] => iblock [HEIGHT] => 882 [WIDTH] => 1500 [FILE_SIZE] => 294110 [CONTENT_TYPE] => image/jpeg [SUBDIR] => iblock/49b/aerui78zm6ajo8bo8aqmttnp04o2u60r [FILE_NAME] => r_pm_7.jpg [ORIGINAL_NAME] => r_pm_7.jpg [DESCRIPTION] => [HANDLER_ID] => [EXTERNAL_ID] => d0a4791812b68ea3685940e16fa529c5 [~src] => [SRC] => /upload/iblock/49b/aerui78zm6ajo8bo8aqmttnp04o2u60r/r_pm_7.jpg [UNSAFE_SRC] => /upload/iblock/49b/aerui78zm6ajo8bo8aqmttnp04o2u60r/r_pm_7.jpg [SAFE_SRC] => /upload/iblock/49b/aerui78zm6ajo8bo8aqmttnp04o2u60r/r_pm_7.jpg [ALT] => Summary report on results of clinical trial of medicinal product Areplivir [TITLE] => Summary report on results of clinical trial of medicinal product Areplivir ) [~PREVIEW_PICTURE] => 1614 [LANG_DIR] => /en/ [~LANG_DIR] => /en/ [CODE] => summary-report [~CODE] => summary-report [EXTERNAL_ID] => 1370 [~EXTERNAL_ID] => 1370 [IBLOCK_TYPE_ID] => informationLang [~IBLOCK_TYPE_ID] => informationLang [IBLOCK_CODE] => [~IBLOCK_CODE] => [IBLOCK_EXTERNAL_ID] => 33 [~IBLOCK_EXTERNAL_ID] => 33 [LID] => en [~LID] => en [EDIT_LINK] => [DELETE_LINK] => [DISPLAY_ACTIVE_FROM] => 17 August 2020 [FIELDS] => Array ( ) [PROPERTIES] => Array ( [SOURCE] => Array ( [ID] => 185 [IBLOCK_ID] => 35 [NAME] => Направление [ACTIVE] => Y [SORT] => 100 [CODE] => SOURCE [DEFAULT_VALUE] => [PROPERTY_TYPE] => L [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => Y [XML_ID] => 177 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Направление [~DEFAULT_VALUE] => [VALUE_ENUM] => Array ( [0] => Treatment for COVID-19 ) [VALUE_XML_ID] => Array ( [0] => covid ) [VALUE_SORT] => Array ( [0] => 100 ) [VALUE] => Array ( [0] => Treatment for COVID-19 ) [PROPERTY_VALUE_ID] => Array ( [0] => 115323 ) [VALUE_ENUM_ID] => Array ( [0] => 168 ) [DESCRIPTION] => Array ( [0] => ) [~VALUE] => Array ( [0] => Treatment for COVID-19 ) [~DESCRIPTION] => Array ( [0] => ) ) [LINK] => Array ( [ID] => 186 [IBLOCK_ID] => 35 [NAME] => Ссылка [ACTIVE] => Y [SORT] => 200 [CODE] => LINK [DEFAULT_VALUE] => [PROPERTY_TYPE] => S [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => N [XML_ID] => 188 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Ссылка [~DEFAULT_VALUE] => [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [VALUE] => [PROPERTY_VALUE_ID] => [DESCRIPTION] => [~DESCRIPTION] => [~VALUE] => ) [FILES] => Array ( [ID] => 187 [IBLOCK_ID] => 35 [NAME] => Файлы [ACTIVE] => Y [SORT] => 900 [CODE] => FILES [DEFAULT_VALUE] => [PROPERTY_TYPE] => F [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => Y [XML_ID] => 182 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => Y [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Файлы [~DEFAULT_VALUE] => [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [VALUE] => Array ( [0] => 1613 ) [PROPERTY_VALUE_ID] => Array ( [0] => 115310 ) [DESCRIPTION] => Array ( [0] => ) [~VALUE] => Array ( [0] => 1613 ) [~DESCRIPTION] => Array ( [0] => ) ) ) [DISPLAY_PROPERTIES] => Array ( [SOURCE] => Array ( [ID] => 185 [IBLOCK_ID] => 35 [NAME] => Направление [ACTIVE] => Y [SORT] => 100 [CODE] => SOURCE [DEFAULT_VALUE] => [PROPERTY_TYPE] => L [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => Y [XML_ID] => 177 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Направление [~DEFAULT_VALUE] => [VALUE_ENUM] => Array ( [0] => Treatment for COVID-19 ) [VALUE_XML_ID] => Array ( [0] => covid ) [VALUE_SORT] => Array ( [0] => 100 ) [VALUE] => Array ( [0] => Treatment for COVID-19 ) [PROPERTY_VALUE_ID] => Array ( [0] => 115323 ) [VALUE_ENUM_ID] => Array ( [0] => 168 ) [DESCRIPTION] => Array ( [0] => ) [~VALUE] => Array ( [0] => Treatment for COVID-19 ) [~DESCRIPTION] => Array ( [0] => ) [DISPLAY_VALUE] => Treatment for COVID-19 ) ) [IPROPERTY_VALUES] => Array ( ) ) [2] => Array ( [ID] => 1368 [~ID] => 1368 [IBLOCK_ID] => 35 [~IBLOCK_ID] => 35 [IBLOCK_SECTION_ID] => [~IBLOCK_SECTION_ID] => [NAME] => A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? [~NAME] => A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? [ACTIVE_FROM] => 04/30/2020 [~ACTIVE_FROM] => 04/30/2020 [TIMESTAMP_X] => 27.01.2022 18:14:29 [~TIMESTAMP_X] => 27.01.2022 18:14:29 [DETAIL_PAGE_URL] => /en/research/a-review/ [~DETAIL_PAGE_URL] => /en/research/a-review/ [LIST_PAGE_URL] => /en/research/ [~LIST_PAGE_URL] => /en/research/ [DETAIL_TEXT] => [~DETAIL_TEXT] => [DETAIL_TEXT_TYPE] => text [~DETAIL_TEXT_TYPE] => text [PREVIEW_TEXT] => Repurposing broad-spectrum antivirals is an immediate treatment opportunity for 2019 coronavirus disease (COVID-19). Favipiravir is an antiviral previously indicated for influenza and Ebola, which has shown some promise in early trials for treatment of COVI D-19. We aim to review existing favipiravir safety evidence, which is vital to informing the potential future use of favipiravir in COVID-19. [~PREVIEW_TEXT] => Repurposing broad-spectrum antivirals is an immediate treatment opportunity for 2019 coronavirus disease (COVID-19). Favipiravir is an antiviral previously indicated for influenza and Ebola, which has shown some promise in early trials for treatment of COVI D-19. We aim to review existing favipiravir safety evidence, which is vital to informing the potential future use of favipiravir in COVID-19. [PREVIEW_TEXT_TYPE] => text [~PREVIEW_TEXT_TYPE] => text [PREVIEW_PICTURE] => Array ( [ID] => 1618 [TIMESTAMP_X] => Bitrix\Main\Type\DateTime Object ( [userTimeEnabled:protected] => 1 [value:protected] => DateTime Object ( [date] => 2022-01-27 18:14:29.000000 [timezone_type] => 3 [timezone] => Europe/Moscow ) ) [MODULE_ID] => iblock [HEIGHT] => 882 [WIDTH] => 1500 [FILE_SIZE] => 226036 [CONTENT_TYPE] => image/jpeg [SUBDIR] => iblock/298/fabkg11fmtjvaeclvycwhjf4zghe6gpi [FILE_NAME] => r_pm_4.jpg [ORIGINAL_NAME] => r_pm_4.jpg [DESCRIPTION] => [HANDLER_ID] => [EXTERNAL_ID] => cebe5c9c8a41bc331af3c8e86c4b56d2 [~src] => [SRC] => /upload/iblock/298/fabkg11fmtjvaeclvycwhjf4zghe6gpi/r_pm_4.jpg [UNSAFE_SRC] => /upload/iblock/298/fabkg11fmtjvaeclvycwhjf4zghe6gpi/r_pm_4.jpg [SAFE_SRC] => /upload/iblock/298/fabkg11fmtjvaeclvycwhjf4zghe6gpi/r_pm_4.jpg [ALT] => A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? [TITLE] => A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? ) [~PREVIEW_PICTURE] => 1618 [LANG_DIR] => /en/ [~LANG_DIR] => /en/ [CODE] => a-review [~CODE] => a-review [EXTERNAL_ID] => 1368 [~EXTERNAL_ID] => 1368 [IBLOCK_TYPE_ID] => informationLang [~IBLOCK_TYPE_ID] => informationLang [IBLOCK_CODE] => [~IBLOCK_CODE] => [IBLOCK_EXTERNAL_ID] => 33 [~IBLOCK_EXTERNAL_ID] => 33 [LID] => en [~LID] => en [EDIT_LINK] => [DELETE_LINK] => [DISPLAY_ACTIVE_FROM] => 10 November 2022 [FIELDS] => Array ( ) [PROPERTIES] => Array ( [SOURCE] => Array ( [ID] => 185 [IBLOCK_ID] => 35 [NAME] => Направление [ACTIVE] => Y [SORT] => 100 [CODE] => SOURCE [DEFAULT_VALUE] => [PROPERTY_TYPE] => L [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => Y [XML_ID] => 177 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Направление [~DEFAULT_VALUE] => [VALUE_ENUM] => Array ( [0] => Treatment for COVID-19 ) [VALUE_XML_ID] => Array ( [0] => covid ) [VALUE_SORT] => Array ( [0] => 100 ) [VALUE] => Array ( [0] => Treatment for COVID-19 ) [PROPERTY_VALUE_ID] => Array ( [0] => 118822 ) [VALUE_ENUM_ID] => Array ( [0] => 168 ) [DESCRIPTION] => Array ( [0] => ) [~VALUE] => Array ( [0] => Treatment for COVID-19 ) [~DESCRIPTION] => Array ( [0] => ) ) [LINK] => Array ( [ID] => 186 [IBLOCK_ID] => 35 [NAME] => Ссылка [ACTIVE] => Y [SORT] => 200 [CODE] => LINK [DEFAULT_VALUE] => [PROPERTY_TYPE] => S [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => N [XML_ID] => 188 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Ссылка [~DEFAULT_VALUE] => [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [VALUE] => [PROPERTY_VALUE_ID] => [DESCRIPTION] => [~DESCRIPTION] => [~VALUE] => ) [FILES] => Array ( [ID] => 187 [IBLOCK_ID] => 35 [NAME] => Файлы [ACTIVE] => Y [SORT] => 900 [CODE] => FILES [DEFAULT_VALUE] => [PROPERTY_TYPE] => F [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => Y [XML_ID] => 182 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => Y [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Файлы [~DEFAULT_VALUE] => [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [VALUE] => Array ( [0] => 1610 ) [PROPERTY_VALUE_ID] => Array ( [0] => 115307 ) [DESCRIPTION] => Array ( [0] => ) [~VALUE] => Array ( [0] => 1610 ) [~DESCRIPTION] => Array ( [0] => ) ) ) [DISPLAY_PROPERTIES] => Array ( [SOURCE] => Array ( [ID] => 185 [IBLOCK_ID] => 35 [NAME] => Направление [ACTIVE] => Y [SORT] => 100 [CODE] => SOURCE [DEFAULT_VALUE] => [PROPERTY_TYPE] => L [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => Y [XML_ID] => 177 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Направление [~DEFAULT_VALUE] => [VALUE_ENUM] => Array ( [0] => Treatment for COVID-19 ) [VALUE_XML_ID] => Array ( [0] => covid ) [VALUE_SORT] => Array ( [0] => 100 ) [VALUE] => Array ( [0] => Treatment for COVID-19 ) [PROPERTY_VALUE_ID] => Array ( [0] => 118822 ) [VALUE_ENUM_ID] => Array ( [0] => 168 ) [DESCRIPTION] => Array ( [0] => ) [~VALUE] => Array ( [0] => Treatment for COVID-19 ) [~DESCRIPTION] => Array ( [0] => ) [DISPLAY_VALUE] => Treatment for COVID-19 ) ) [IPROPERTY_VALUES] => Array ( ) ) [3] => Array ( [ID] => 1371 [~ID] => 1371 [IBLOCK_ID] => 35 [~IBLOCK_ID] => 35 [IBLOCK_SECTION_ID] => [~IBLOCK_SECTION_ID] => [NAME] => Experimental Treatment with Favipiravir for COVID-19: An Open-Label [~NAME] => Experimental Treatment with Favipiravir for COVID-19: An Open-Label [ACTIVE_FROM] => 03/12/2020 [~ACTIVE_FROM] => 03/12/2020 [TIMESTAMP_X] => 26.01.2022 17:49:49 [~TIMESTAMP_X] => 26.01.2022 17:49:49 [DETAIL_PAGE_URL] => /en/research/experimental-treatment/ [~DETAIL_PAGE_URL] => /en/research/experimental-treatment/ [LIST_PAGE_URL] => /en/research/ [~LIST_PAGE_URL] => /en/research/ [DETAIL_TEXT] => [~DETAIL_TEXT] => [DETAIL_TEXT_TYPE] => text [~DETAIL_TEXT_TYPE] => text [PREVIEW_TEXT] => Control Study. [~PREVIEW_TEXT] => Control Study. [PREVIEW_TEXT_TYPE] => text [~PREVIEW_TEXT_TYPE] => text [PREVIEW_PICTURE] => Array ( [ID] => 1617 [TIMESTAMP_X] => Bitrix\Main\Type\DateTime Object ( [userTimeEnabled:protected] => 1 [value:protected] => DateTime Object ( [date] => 2022-01-26 17:49:49.000000 [timezone_type] => 3 [timezone] => Europe/Moscow ) ) [MODULE_ID] => iblock [HEIGHT] => 882 [WIDTH] => 1500 [FILE_SIZE] => 294810 [CONTENT_TYPE] => image/jpeg [SUBDIR] => iblock/087/luy5wkmj0u0iuz4irb41refq73zyo112 [FILE_NAME] => r_pm_3.jpg [ORIGINAL_NAME] => r_pm_3.jpg [DESCRIPTION] => [HANDLER_ID] => [EXTERNAL_ID] => f9a552ea4ac4f20679686113c41e55fd [~src] => [SRC] => /upload/iblock/087/luy5wkmj0u0iuz4irb41refq73zyo112/r_pm_3.jpg [UNSAFE_SRC] => /upload/iblock/087/luy5wkmj0u0iuz4irb41refq73zyo112/r_pm_3.jpg [SAFE_SRC] => /upload/iblock/087/luy5wkmj0u0iuz4irb41refq73zyo112/r_pm_3.jpg [ALT] => Experimental Treatment with Favipiravir for COVID-19: An Open-Label [TITLE] => Experimental Treatment with Favipiravir for COVID-19: An Open-Label ) [~PREVIEW_PICTURE] => 1617 [LANG_DIR] => /en/ [~LANG_DIR] => /en/ [CODE] => experimental-treatment [~CODE] => experimental-treatment [EXTERNAL_ID] => 1371 [~EXTERNAL_ID] => 1371 [IBLOCK_TYPE_ID] => informationLang [~IBLOCK_TYPE_ID] => informationLang [IBLOCK_CODE] => [~IBLOCK_CODE] => [IBLOCK_EXTERNAL_ID] => 33 [~IBLOCK_EXTERNAL_ID] => 33 [LID] => en [~LID] => en [EDIT_LINK] => [DELETE_LINK] => [DISPLAY_ACTIVE_FROM] => 3 December 2020 [FIELDS] => Array ( ) [PROPERTIES] => Array ( [SOURCE] => Array ( [ID] => 185 [IBLOCK_ID] => 35 [NAME] => Направление [ACTIVE] => Y [SORT] => 100 [CODE] => SOURCE [DEFAULT_VALUE] => [PROPERTY_TYPE] => L [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => Y [XML_ID] => 177 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Направление [~DEFAULT_VALUE] => [VALUE_ENUM] => Array ( [0] => Treatment for COVID-19 ) [VALUE_XML_ID] => Array ( [0] => covid ) [VALUE_SORT] => Array ( [0] => 100 ) [VALUE] => Array ( [0] => Treatment for COVID-19 ) [PROPERTY_VALUE_ID] => Array ( [0] => 115322 ) [VALUE_ENUM_ID] => Array ( [0] => 168 ) [DESCRIPTION] => Array ( [0] => ) [~VALUE] => Array ( [0] => Treatment for COVID-19 ) [~DESCRIPTION] => Array ( [0] => ) ) [LINK] => Array ( [ID] => 186 [IBLOCK_ID] => 35 [NAME] => Ссылка [ACTIVE] => Y [SORT] => 200 [CODE] => LINK [DEFAULT_VALUE] => [PROPERTY_TYPE] => S [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => N [XML_ID] => 188 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Ссылка [~DEFAULT_VALUE] => [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [VALUE] => [PROPERTY_VALUE_ID] => [DESCRIPTION] => [~DESCRIPTION] => [~VALUE] => ) [FILES] => Array ( [ID] => 187 [IBLOCK_ID] => 35 [NAME] => Файлы [ACTIVE] => Y [SORT] => 900 [CODE] => FILES [DEFAULT_VALUE] => [PROPERTY_TYPE] => F [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => Y [XML_ID] => 182 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => Y [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Файлы [~DEFAULT_VALUE] => [VALUE_ENUM] => [VALUE_XML_ID] => [VALUE_SORT] => [VALUE] => Array ( [0] => 1616 ) [PROPERTY_VALUE_ID] => Array ( [0] => 115311 ) [DESCRIPTION] => Array ( [0] => ) [~VALUE] => Array ( [0] => 1616 ) [~DESCRIPTION] => Array ( [0] => ) ) ) [DISPLAY_PROPERTIES] => Array ( [SOURCE] => Array ( [ID] => 185 [IBLOCK_ID] => 35 [NAME] => Направление [ACTIVE] => Y [SORT] => 100 [CODE] => SOURCE [DEFAULT_VALUE] => [PROPERTY_TYPE] => L [ROW_COUNT] => 1 [COL_COUNT] => 30 [LIST_TYPE] => L [MULTIPLE] => Y [XML_ID] => 177 [FILE_TYPE] => [MULTIPLE_CNT] => 5 [LINK_IBLOCK_ID] => 0 [WITH_DESCRIPTION] => N [SEARCHABLE] => N [FILTRABLE] => N [IS_REQUIRED] => N [VERSION] => 1 [USER_TYPE] => [USER_TYPE_SETTINGS] => [HINT] => [~NAME] => Направление [~DEFAULT_VALUE] => [VALUE_ENUM] => Array ( [0] => Treatment for COVID-19 ) [VALUE_XML_ID] => Array ( [0] => covid ) [VALUE_SORT] => Array ( [0] => 100 ) [VALUE] => Array ( [0] => Treatment for COVID-19 ) [PROPERTY_VALUE_ID] => Array ( [0] => 115322 ) [VALUE_ENUM_ID] => Array ( [0] => 168 ) [DESCRIPTION] => Array ( [0] => ) [~VALUE] => Array ( [0] => Treatment for COVID-19 ) [~DESCRIPTION] => Array ( [0] => ) [DISPLAY_VALUE] => Treatment for COVID-19 ) ) [IPROPERTY_VALUES] => Array ( ) ) ) 1
Expert board: "Possibilities of etiotropic therapy for respiratory infections caused by RNA viruses"
26 Apr 2021
Treatment for COVID-19
Expert board: "Possibilities of etiotropic therapy for respiratory infections caused by RNA viruses"
On April 26, 2021, in Moscow, under the auspices of the consortium of the academic community for the study of coronavirus infection, an expert council of the Russian Scientific Medical Society of Physicians was held dedicated to modern aspects of etiotropic therapy for the new coronavirus infection and other diseases caused by RNA viruses.
Summary report on results of clinical trial of medicinal product Areplivir
17 Aug 2020
Treatment for COVID-19
Summary report on results of clinical trial of medicinal product Areplivir
Open randomized multicenter comparative study on the efficacy and safety of AREPLIVIR film-coated tablets (PROMOMED RUS LLC, Russia) in patients hospitalized with COVID-19
A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?
30 Apr 2020
Treatment for COVID-19
A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?
Repurposing broad-spectrum antivirals is an immediate treatment opportunity for 2019 coronavirus disease (COVID-19). Favipiravir is an antiviral previously indicated for influenza and Ebola, which has shown some promise in early trials for treatment of COVI D-19. We aim to review existing favipiravir safety evidence, which is vital to informing the potential future use of favipiravir in COVID-19.
Experimental Treatment with Favipiravir for COVID-19: An Open-Label
12 Mar 2020
Treatment for COVID-19
Experimental Treatment with Favipiravir for COVID-19: An Open-Label
Control Study.